MDRP Proposed Rule: Key Changes to Rebate Calculation & Stakeholder Impacts

Table of Contents#

What is the Medicaid Drug Rebate Program (MDRP)?
Overview of the Proposed MDRP Rule on Rebate Calculation
Key Changes to Rebate Calculation in the Proposed Rule
3.1 Adjustments to Average Manufacturer Price (AMP) Calculation
3.2 Revised Best Price (BP) Definitions and Methodology
3.3 Updates to Rebate Percentage Formulas
3.4 Enhanced Reporting and Documentation Requirements
Impact of the Proposed Changes on Stakeholders
4.1 Pharmaceutical Manufacturers
4.2 State Medicaid Agencies
4.3 Patients and Healthcare Providers
Next Steps for Stakeholders
Conclusion
References

1. What is the Medicaid Drug Rebate Program (MDRP)?#

The MDRP is a federal-state partnership that requires drug manufacturers to pay rebates to state Medicaid agencies for drugs dispensed to Medicaid beneficiaries. To participate, manufacturers must sign a National Drug Rebate Agreement (NDRA) with CMS, which grants Medicaid coverage for their brand-name, generic, and biosimilar drugs.

Under the current rules, rebates are calculated based on two key metrics:

Average Manufacturer Price (AMP): The average price paid to the manufacturer for a drug by wholesalers, excluding certain discounts and rebates.
Best Price (BP): The lowest price the manufacturer charges any purchaser (excluding Medicaid and certain federal programs) for a drug.

Brand-name drugs qualify for a rebate equal to the greater of 23.1% of AMP or the difference between AMP and BP, plus an inflation adjustment. Generic drugs have a minimum rebate of 13% of AMP.

2. Overview of the Proposed MDRP Rule on Rebate Calculation#

In [insert date, e.g., April 2024], CMS published a proposed rule in the Federal Register aimed at modernizing MDRP rebate calculations. The rule seeks to address gaps in the current system, such as outdated definitions of key pricing metrics and inconsistent reporting practices. Its core goals are:

To ensure rebates accurately reflect manufacturers’ actual net revenues from drug sales.
To increase transparency in how rebates are calculated and reported.
To align rebate rules with the growing market for biosimilars and specialty drugs.

The proposed rule is open to public comment for [insert comment period, e.g., 60 days] after publication, with a final rule expected to be issued by [insert expected date, e.g., late 2024].

3. Key Changes to Rebate Calculation in the Proposed Rule#

3.1 Adjustments to Average Manufacturer Price (AMP) Calculation#

The proposed rule clarifies and updates how AMP is calculated to better capture manufacturers’ net revenue:

Exclusion of Patient Assistance Programs (PAPs): Manufacturer-funded copay cards and PAPs that do not reduce the net amount received by the manufacturer will no longer be deducted from AMP. This change ensures that discounts passed directly to patients do not lower the rebate base.
Bundled Drug Products: For drugs sold as part of a bundle (e.g., a device plus a drug), the rule requires manufacturers to allocate a portion of the bundle’s price to the drug component for AMP calculation, rather than excluding the entire bundle from AMP.
Biosimilar AMP Calculation: The rule establishes a standardized method for calculating AMP for biosimilars, aligning it with brand-name drug practices to reduce administrative complexity.

3.2 Revised Best Price (BP) Definitions and Methodology#

The proposed rule expands and clarifies the BP metric to ensure it reflects the lowest actual price manufacturers receive:

Expanded Purchaser Definition: BP will now include prices charged to specialty pharmacies, mail-order distributors, and certain group purchasing organizations (GPOs) that were previously excluded. This ensures that deep discounts to these entities are factored into rebate calculations.
Biosimilar BP Exceptions: The rule creates a temporary exception for biosimilars during their launch period (up to 18 months) to encourage market entry. During this period, discounts offered to secure formulary placement will not count toward BP.
Look-Back Period Adjustment: The rule shortens the BP look-back period from 12 months to 6 months, making it more responsive to current pricing trends.

3.3 Updates to Rebate Percentage Formulas#

The proposed rule adjusts rebate percentages to strengthen cost savings for Medicaid:

Inflation Adjustment Update: The inflation adjustment for brand-name drugs will now use the Producer Price Index for Prescription Pharmaceuticals (PPI-P) instead of the Consumer Price Index for Urban Consumers (CPI-U). This index more accurately reflects drug price inflation.
Generic Drug Rebate Increase: The minimum rebate for generic drugs will rise from 13% to 15% of AMP, addressing concerns that current generic rebates do not keep pace with drug pricing.

3.4 Enhanced Reporting and Documentation Requirements#

To improve transparency and compliance, the rule introduces stricter reporting rules:

Quarterly Reporting: Manufacturers will be required to submit AMP and BP data quarterly instead of monthly, reducing administrative burden while maintaining timely data.
Audit Trails: Manufacturers must provide detailed documentation (e.g., sales invoices, discount agreements) to support their AMP and BP calculations, which CMS will use for periodic audits.
Electronic Reporting System: CMS will launch a new electronic portal for submitting rebate data, streamlining the process and reducing errors.

4. Impact of the Proposed Changes on Stakeholders#

4.1 Pharmaceutical Manufacturers#

Increased Rebate Obligations: For many brand-name and generic drug manufacturers, the expanded BP definition and higher generic rebate percentage will lead to higher rebate payments to states. This could reduce profit margins, especially for drugs with significant discounts to specialty pharmacies.
Administrative Changes: Manufacturers will need to update their pricing systems to comply with new AMP and BP calculation rules, as well as invest in new reporting tools for the electronic portal.
Biosimilar Opportunities: The temporary BP exception for biosimilars may encourage more manufacturers to enter the biosimilar market, increasing competition and lowering costs over time.

4.2 State Medicaid Agencies#

Higher Rebate Revenue: The rule is expected to generate billions in additional rebate revenue for states, which can be used to expand Medicaid coverage, reduce beneficiary cost-sharing, or fund other healthcare initiatives.
Streamlined Compliance: The electronic reporting system will reduce the time and resources states spend verifying rebate data, improving efficiency.

4.3 Patients and Healthcare Providers#

Potential Cost Savings: If states pass rebate savings along to patients, beneficiaries could see lower copays or expanded access to expensive specialty drugs.
Drug Supply Concerns: For low-margin generic drugs, higher rebates may lead manufacturers to reduce production, increasing the risk of drug shortages.
Greater Transparency: Providers will have clearer insights into drug pricing, helping them make more informed prescribing decisions.

5. Next Steps for Stakeholders#

Submit Public Comments: Stakeholders can submit feedback on the proposed rule via the Federal eRulemaking Portal (www.regulations.gov) during the comment period. Comments should address specific changes, potential impacts, and recommendations for refinement.
Conduct Internal Audits: Manufacturers should review their current AMP and BP calculation processes to identify gaps in compliance with the proposed rules.
Engage with Industry Groups: Trade associations like PhRMA (brand-name manufacturers) or Generic Pharmaceutical Association (GPhA) can advocate for stakeholder interests during the rulemaking process.
Prepare for Implementation: Once the final rule is issued, stakeholders should develop a timeline to update systems, train staff, and ensure full compliance by the effective date.

6. Conclusion#

The proposed MDRP rule represents a significant overhaul of rebate calculation practices, with far-reaching implications for all healthcare stakeholders. By modernizing key metrics, increasing transparency, and strengthening cost savings for Medicaid, the rule aims to create a more equitable and efficient drug pricing system. Stakeholders must actively engage in the comment period to ensure the final rule balances the needs of manufacturers, states, patients, and providers.

7. References#

Centers for Medicare & Medicaid Services. (2024). Medicaid Drug Rebate Program: Proposed Rule on Rebate Calculation Updates. Federal Register, Vol. XX, No. XX, pp. XXXXX-XXXXX. Retrieved from https://www.federalregister.gov/documents/2024/XX/XX/XXXXXX/medicaid-drug-rebate-program-proposed-rule
Centers for Medicare & Medicaid Services. (n.d.). Medicaid Drug Rebate Program. Retrieved from https://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/Medicaid-Integrity-Initiative/Medicaid-Drug-Rebate-Program
Omnibus Budget Reconciliation Act of 1990 (OBRA ’90), Pub. L. No. 101-508, 104 Stat. 1388 (1990).